Grant Balfour agreed to a two-year, $15 million contract with the Orioles in mid-December before they claimed he failed a physical exam and nixed the deal.
More than a month later Balfour signed a two-year, $12 million contract with the Rays and at the press conference yesterday he repeatedly stressed that he’s “100 percent healthy” while implying that the Orioles did him dirty:
I’ve had an eventful offseason to say the least. That was a bit of a stressful thing to see that go down knowing that I knew I was perfectly healthy. I did take a physical [for the Rays], and I passed with flying colors, apparently.
What happened there in Baltimore is in the past. It was something that, to be honest with you, I had other offers on the table and other teams telling me that I didn’t have to take a physical because they believed in my medicals and everything that they’d heard, that I didn’t even have to go and take a physical with them.
I’m totally healthy–100 percent healthy–and you’ll see that when I take the field April 1 here. I’m looking forward to it.
Balfour ultimately landed in a good spot, with a good team and a multi-year contract at age 37, but the Orioles backing out of the original deal cost him $3 million and for a pitcher getting what may be his last big payday that’s probably pretty tough to swallow.
It should be interesting when he takes the mound against Baltimore for the first time.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.